BiotechTube

Colesevelam hydrochloride film-coated tablets + Placebo

ApprovedCompleted
0 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Familial Hypercholesterolemia

Conditions

Familial Hypercholesterolemia

Trial Timeline

Aug 1, 2007 → Oct 1, 2009

NCT ID
NCT00655265

About Colesevelam hydrochloride film-coated tablets + Placebo

Colesevelam hydrochloride film-coated tablets + Placebo is a approved stage product being developed by Sanofi for Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00655265. Target conditions include Familial Hypercholesterolemia.

What happened to similar drugs?

4 of 20 similar drugs in Familial Hypercholesterolemia were approved

Approved (4) Terminated (4) Active (14)
✅EvolocumabAmgenApproved
✅evolocumabAmgenApproved
✅AnakinraSwedish Orphan BiovitrumApproved
✅PraluentSanofiApproved
🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
🔄rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00655265ApprovedCompleted

Competing Products

20 competing products in Familial Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
SHR-1209Jiangsu Hengrui MedicinePhase 2
31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3
40
Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3
40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calciumAstraZenecaPhase 3
40
Rosuvastatin + PlaceboAstraZenecaPhase 3
40
Rosuvastatin 20mgAstraZenecaPhase 3
40
AZD0780 + PlaceboAstraZenecaPhase 3
44
Anacetrapib + Placebo for anacetrapibMerckPhase 3
40
Statins and EzetimibeMerckPre-clinical
22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placeboMerckPhase 3
32
MK-0524A + MK-0524AMerckPhase 1
21
Enlicitide Decanoate + PlaceboMerckPhase 2/3
45
Inclisiran + PlaceboNovartisPhase 3
40
DFV890NovartisPhase 2
35
CanakinumabNovartisPhase 2
35
Inclisiran Sodium for injection + Placebo + PlacebosNovartisPhase 3
40
LCQ908 + PlaceboNovartisPhase 3
40
InclisiranNovartisPhase 3
44
Inclisiran + PlaceboNovartisPhase 3
40